Compass Point analyst Merrill Ross downgrades Centerspace (NYSE:CSR) from Buy to Neutral and announces $75 price target.
Expert Ratings for Halozyme Therapeutics
Analysts have provided the following ratings for Halozyme Therapeutics (NASDAQ:HALO) within the last quarter: Bullish Somewhat Bullish Indifferent…